Concord Health Partners

Concord Health Partners is a New York-based growth-stage healthcare investor with a strategic-syndicate posture: the firm raises capital from major US health systems and corporate strategics, deploying that capital into healthcare companies while providing portfolio companies access to a syndicate of health-system pilot partners. The model is distinctive — Concord’s LP base is itself the customer base of many of its portfolio companies — and it gives founders a meaningful operational advantage in selling into health systems. Their healthcare exposure spans digital health, clinical AI, healthcare services, and medtech, with a preference for companies that benefit from health-system relationships and strategic alignment. Stage focus is later — Series B and beyond — with check sizes plausibly $5M to $20M and a willingness to lead or co-lead growth rounds. For healthcare AI founders, Concord is the right partner if you are a Series B or C healthcare AI company with revenue, proven clinical or operational outcomes, and a sales motion that benefits from accelerated health-system relationships. Founders who should approach: growth-stage clinical AI teams selling into hospitals — ambient documentation, RCM, care management, clinical decision support, patient experience — with revenue, strong customer references, and a credible path to expanding within health systems. Founders who should not approach: seed and Series A teams, consumer-only health apps, biotech, and regulated devices needing specialist medtech syndicates. Their value-add is the strategic syndicate — accelerated pilot conversions, health-system board sponsorship, and downstream commercial relationships. Entry path is warm introduction through their LP health systems, growth-stage VCs that co-invest with Concord, or portfolio CEOs.